--(BUSINESS WIRE)--PlaCor, Inc., based in Plymouth, Minnesota, is a privately-held corporation which is developing a simple, easy to use, proprietary, global, point-of-care test to measure platelet reactivity. Anti-platelet drugs, such as aspirin and Plavix®, are often prescribed by physicians to inhibit platelet reactivity as part of a regimen to reduce the occurrence and severity of heart attacks and strokes. The PlaCor test will be used initially to monitor anti-platelet therapy. The test is available for research purposes only and is currently the subject of a premarket notification review by the Food and Drug Administration pursuant to Section 510(k) of the Food, Drug and Cosmetic Act.
